Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Iterum Therapeutics plc is a biotechnology business based in the US. Iterum Therapeutics shares (ITRM) are listed on the NASDAQ and all prices are listed in US Dollars. Iterum Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of USD$286.7 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$0.451 - USD$4.7 |
---|---|
50-day moving average | USD$1.6198 |
200-day moving average | USD$0.9733 |
Wall St. target price | USD$1.5 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-7.047 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$37,000 |
---|---|
Return on assets TTM | -82.01% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | $1.706 |
Market capitalisation | USD$286.7 million |
TTM: trailing 12 months
There are currently 1.8 million Iterum Therapeutics shares held short by investors – that's known as Iterum Therapeutics's "short interest". This figure is 69.3% down from 6.0 million last month.
There are a few different ways that this level of interest in shorting Iterum Therapeutics shares can be evaluated.
Iterum Therapeutics's "short interest ratio" (SIR) is the quantity of Iterum Therapeutics shares currently shorted divided by the average quantity of Iterum Therapeutics shares traded daily (recently around 14.2 million). Iterum Therapeutics's SIR currently stands at 0.13. In other words for every 100,000 Iterum Therapeutics shares traded daily on the market, roughly 130 shares are currently held short.
However Iterum Therapeutics's short interest can also be evaluated against the total number of Iterum Therapeutics shares, or, against the total number of tradable Iterum Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Iterum Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Iterum Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.1271% of the tradable shares (for every 100,000 tradable Iterum Therapeutics shares, roughly 127 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Iterum Therapeutics.
Find out more about how you can short Iterum Therapeutics stock.
We're not expecting Iterum Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Iterum Therapeutics's shares have ranged in value from as little as $0.451 up to $4.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iterum Therapeutics's is 1.3749. This would suggest that Iterum Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.